US FDA approves Arcutis' drug to treat chronic skin disease
Dec 15 (Reuters) - The U.S. Food and Drug Administration
(FDA) on Friday approved Arcutis Biotherapeutics' ARQT.O drug
for treating a skin condition called seborrheic dermatitis in
individuals nine years of age and older.
(Reporting by Pratik Jain in Bengaluru; Editing by Shailesh
Kuber)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4